ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 96 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $130,305 | -57.6% | 118,459 | -52.2% | 0.00% | -100.0% |
Q1 2024 | $307,117 | +188.8% | 247,675 | +144.5% | 0.00% | – |
Q4 2023 | $106,344 | -83.4% | 101,280 | +8.5% | 0.00% | -100.0% |
Q3 2023 | $639,694 | -53.6% | 93,386 | -29.8% | 0.00% | -50.0% |
Q2 2023 | $1,379,583 | +304.1% | 133,036 | +215.3% | 0.00% | +300.0% |
Q1 2023 | $341,398 | +126.1% | 42,200 | -54.9% | 0.00% | 0.0% |
Q2 2020 | $151,000 | +55.7% | 93,518 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $97,000 | -96.0% | 93,518 | -92.8% | 0.00% | -87.5% |
Q4 2019 | $2,449,000 | -39.3% | 1,295,966 | -65.3% | 0.01% | -46.7% |
Q3 2019 | $4,034,000 | -10.5% | 3,734,793 | +81.5% | 0.02% | -6.2% |
Q2 2019 | $4,507,000 | -36.5% | 2,057,936 | +73.6% | 0.02% | -40.7% |
Q1 2019 | $7,101,000 | +44.2% | 1,185,528 | +77.9% | 0.03% | +22.7% |
Q4 2018 | $4,925,000 | -15.8% | 666,430 | +65.5% | 0.02% | +4.8% |
Q3 2018 | $5,846,000 | +260.6% | 402,624 | +396.1% | 0.02% | +200.0% |
Q2 2018 | $1,621,000 | – | 81,166 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |